Alzheimer’s under scrutiny: the amyloid hypothesis hits a turning point

The piece chronicles how the once-dominant amyloid-β hypothesis has been undermined by multiple retractions and high-profile drug failures, fueling debate over data integrity and regulatory controversy. While FDA-approved antibodies targeting amyloid-β have had limited or questionable benefits and come with serious risks, researchers are increasingly exploring alternatives—such as neuroinflammation, infections, the gut microbiome, and APOE4-related pathways—suggesting Alzheimer's may result from multiple interacting factors rather than a single cause. The article highlights the persistence of amyloid research despite misconduct findings and casts doubt on a simple cure tied to amyloid-β clearance.